Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of its Duchenne muscular dystrophy (DMD) cell therapy candidate met its endpoints. The Phase III HOPE-3 trial ...
Duchenne muscular dystrophy (DMD) is an X-linked genetic disease that causes the muscles—including the heart—to gradually weaken and waste away. Affecting almost exclusively boys and young men, most ...
A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD), and may also slow heart damage in those who already have heart ...
Newswise — LOS ANGELES (July 29, 2026) -- An investigational cell therapy preserved heart and muscle function in boys and young men with Duchenne muscular dystrophy, according to Phase III clinical ...
Duchenne muscular dystrophy is a severe, progressive, X-linked neuromuscular disease affecting approximately one in 5,000 male births. It is caused by mutations in the DMD gene that prevent the ...
A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD), and may also slow heart damage in those who already have heart ...
New York, USA, May 26, 2026 (GLOBE NEWSWIRE) -- Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results